Trials / Unknown
UnknownNCT04989621
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) ：a Single Arm, Open Label, Multi-center Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orelabrutinib and Rituximab | Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1. |
| DRUG | Orelabrutinib | Orelabrutinib 150mg po qd |
Timeline
- Start date
- 2021-08-01
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2021-08-04
- Last updated
- 2022-03-24
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04989621. Inclusion in this directory is not an endorsement.